Aberrations in Lipid Expression and Metabolism in Psoriasis

Nowowiejska, Julia; Baran, Anna; Flisiak, Iwona

doi:10.3390/ijms22126561

Cited by 58 publications

(56 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies analyzing plasma or serum showed altered lipid metabolites in psoriatic patients [ 67 , 68 ]. In psoriatic skin lesions, lipid metabolism abnormalities were also observed [ 69 , 70 ]. And our high-throughput transcriptome analysis of psoriatic skins identified notable differences in genes involved in lipid metabolism [ 71 ].…”

Section: Factors Regulating Psoriatic Keratinocytesmentioning

confidence: 99%

Advances in the pathogenesis of psoriasis: from keratinocyte perspective

et al. 2022

View full text Add to dashboard Cite

Psoriasis is a complex long-lasting inflammatory skin disease with high prevalence and associated comorbidity. It is characterized by epidermal hyperplasia and dermal infiltration of immune cells. Here, we review the role of keratinocytes in the pathogenesis of psoriasis, focusing on factors relevant to genetics, cytokines and receptors, metabolism, cell signaling, transcription factors, non-coding RNAs, antimicrobial peptides, and proteins with other different functions. The critical role of keratinocytes in initiating and maintaining the inflammatory state suggests the great significance of targeting keratinocytes for the treatment of psoriasis.

show abstract

Section: Factors Regulating Psoriatic Keratinocytesmentioning

confidence: 99%

Advances in the pathogenesis of psoriasis: from keratinocyte perspective

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Additional mechanisms for modulation of immune responses in psoriasis are continuously to be explored. For example, recent studies have revealed the roles of metabolic pathways, lipid metabolism, and microbiota in the control of skin homeostasis and inflammation [ 191 , 192 , 193 ]. The exploration of immune modulation mechanisms of psoriasis not only increase our understanding of psoriasis but also accelerate the development of therapeutics for psoriasis.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Development Based on the Immunopathogenic Mechanisms of Psoriasis

et al. 2021

View full text Add to dashboard Cite

Psoriasis, a complex inflammatory autoimmune skin disorder that affects 2–3% of the global population, is thought to be genetically predetermined and induced by environmental and immunological factors. In the past decades, basic and clinical studies have significantly expanded knowledge on the molecular, cellular, and immunological mechanisms underlying the pathogenesis of psoriasis. Based on these pathogenic mechanisms, the current disease model emphasizes the role of aberrant Th1 and Th17 responses. Th1 and Th17 immune responses are regulated by a complex network of different cytokines, including TNF-α, IL-17, and IL-23; signal transduction pathways downstream to the cytokine receptors; and various activated transcription factors, including NF-κB, interferon regulatory factors (IRFs), and signal transducer and activator of transcriptions (STATs). The biologics developed to specifically target the cytokines have achieved a better efficacy and safety for the systemic management of psoriasis compared with traditional treatments. Nevertheless, the current therapeutics can only alleviate the symptoms; there is still no cure for psoriasis. Therefore, the development of more effective, safe, and affordable therapeutics for psoriasis is important. In this review, we discussed the current trend of therapeutic development for psoriasis based on the recent discoveries in the immune modulation of the inflammatory response in psoriasis.

show abstract

“…Thus, currently psoriasis is definitely more than skin deep and closely related to numerous cardiometabolic disorders (CMDs), including obesity, diabetes mellitus (DM), dyslipidemia, and hypertension, which make up the metabolic syndrome (MS), as well as non-alcoholic fatty liver disease (NAFLD) and cardiovascular diseases (CVD) [ 2 , 3 , 4 ]. It has been widely proven that the higher rate of comorbidities is related to psoriasis severity [ 5 , 6 ]. Persons with psoriasis have shortened life expectancy of over 5 years mainly due to CVD and increased relative risk of mortality of 1.53 in comparison to 1.12 in the general population [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

“…Psoriatics with severe form present a higher rate of ischemic heart diseases but also have additional absolute risk of 6.2% of a major adverse cardiovascular event (MACE) within 10 years of psoriasis history compared to the healthy population [ 2 , 8 ]. The multidirectional relationship of psoriasis with numerous comorbidities is translated by common genetic or immunological pathways, oxidative stress, as well as systemic metabolically driven inflammation which is important in psoriasis pathogenesis and consequently leads to the development of atherosclerosis, insulin resistance, and CMDs [ 3 , 4 , 5 ]. For years, researchers have been constantly looking for novel modulators of metaflammation in psoriasis to reduce the risk of internal disorders or use as potential targets for therapeutic intervention.…”

Section: Introductionmentioning

confidence: 99%

Galectin-3 as a Novel Multifaceted and Not Only Cardiovascular Biomarker in Patients with Psoriasis with Regard to Systemic Treatment—Preliminary Data

Baran

Kiluk

Nowowiejska

et al. 2022

Biology

Self Cite

View full text Add to dashboard Cite

Galectin-3 (gal-3) is a multifunctional regulator of various biological processes and diseases, which are common comorbidities in psoriasis. Data regarding potential diagnostic role of gal-3 in psoriasis are insufficient. Serum gal-3 levels were evaluated before and after twelve weeks of treatment with acitretin or methotrexate in 31 patients with plaque-type psoriasis and compared to 11 healthy control group. The mean serum galectin-3 level in patients with psoriasis was significantly higher compared to the control group (p < 0.01). In patients with obesity and long-lasting psoriasis (>20 years) positive relations of gal-3 and PASI were noted. In psoriatics with low gal-3 levels, positive correlations between the gal-3 and BMI, glucose level, and with the latter in short-lasting psoriasis (<20 years) were noted. In the long history of psoriasis, gal-3 was negatively correlated with lipids levels. The Gal-3 level might be a multifaceted modulator of the course of psoriasis and predictive factor of cardiometabolic comorbidities’ development, especially in patients with a long history of the disease or obesity. Patients with low serum gal-3 and short history of psoriasis are presumably at greater risk of diabetes. In patients with long-lasting psoriasis and concomitant obesity, gal-3 may exert a protective role against dyslipidemia or perhaps further CMD development.

show abstract

Aberrations in Lipid Expression and Metabolism in Psoriasis

Cited by 58 publications

References 70 publications

Advances in the pathogenesis of psoriasis: from keratinocyte perspective

Advances in the pathogenesis of psoriasis: from keratinocyte perspective

Therapeutic Development Based on the Immunopathogenic Mechanisms of Psoriasis

Galectin-3 as a Novel Multifaceted and Not Only Cardiovascular Biomarker in Patients with Psoriasis with Regard to Systemic Treatment—Preliminary Data

Contact Info

Product

Resources

About